Carbon Air Filter,Active Air Carbon Filter,Activated Carbon Air Filter,Carbon Air Filter System Guangdong Zhengshang Electrical Technology Co., Ltd. , https://www.zengsung.com
China's Pharmaceutical Industry Upgrade Leads to International Helping Hands
China's pharmaceutical industry has experienced the era of GMP certification and entered the era of controllable production. Now many companies are taking steps to change their credentials. If we say that the first certification is the process of eliminating inferior companies, then renewal is seen by many companies as the process of upgrading an excellent company. Then, how will the upgrade of excellent companies be achieved?
In fact, in addition to the self-requirements and self-regulation of mature European and American markets as the starting point for hardware facilities such as production equipment, more and more Chinese companies have more expectation and investment in software-product technology and product innovation. The result of this soft and hard progress will surely be the upgrading of China's pharmaceutical industry. Some authoritative organizations also believe that in the next 10 years, China’s increase in the world’s pharmaceutical market share and the short-term development of China’s pharmaceutical economy over the world’s average speed will increase the number of multinational companies (such as biopharmaceutical companies) related to the pharmaceutical industry. Greater China's investment in China has accelerated the upgrading of China's pharmaceutical industry while winning commercial interests.
The reporter recently visited GE Healthcare's 85 million U.S. dollar life science research center in Shanghai's Zhangjiang, and Yu Dejian, president of the Greater China Region of the Department of Life Sciences, said that China’s biotechnology has great potential both domestically and exportably. In 2007 alone, Asia Pacific The technology market has provided it with more than $41 billion in opportunity.
According to statistics, the proportion of Chinese pharmaceutical companies in biopharmaceuticals has been continuously rising from less than 10% to more than 10%, and the momentum of development is still rapid, showing strong market potential. When the author visited the site, he saw that the above life science research center had a FastTrak training base to provide technical training for Asian and Chinese companies. At present, more than 30 Chinese companies have received training here. Yu Dejian said that they attach great importance to the research and development of traditional Chinese medicine in China. While providing training for Chinese companies, they are actively conducting research together with corporate R&D personnel and university researchers, and there have been breakthroughs.
At the same time, the growth of the Chinese pharmaceutical industry has also helped MNCs expand their business in China.
Take Tonghua Dongbao, China's largest insulin manufacturer, as an example. They currently use GE Healthcare's largest filter system. Yu Dejian said with great confidence that there are signs of stagnation or even subsidence in other regions of the world. However, the Chinese market is very stable. GE’s global management will continue to invest in China, and its Life Sciences Department will also expand its recruitment staff in 2009. To meet the needs of Chinese customers.
This is not a case. For nearly 20 years, Carlecon has been a global leader in the development, application and technical support of formula coating and other accessories. In order to better serve the ever-changing needs of local customers in China, the innovative formulation center invested by Colorcon in 2008 was put into use. The establishment of the center will better help domestic pharmaceutical companies complete the project research objectives in a shorter period of time - from product concept to the development of pharmaceutical formulations until the final production, shorten the time to market for new products for the domestic pharmaceutical companies in the future development and Winning in competition provides strong support. In an interview with the reporter, Colorcon Asia-Pacific Technical Director said that with the improvement of the market mechanism, the Chinese pharmaceutical industry will usher in yet another opportunity for development. “At present, the domestic market is mainly in the generic market, and there is a lot of demand for original medicines in Europe and the United States. The main difference is in the formulation and clinical experience. The establishment of an innovative formulation center is expected to promote the development of the pharmaceutical formulation field in China at a fundamental level.â€
As the world's largest and most extensively involved filter, separation and purification business, Pall Corporation has also set up R&D and customer service centers in Shanghai this year to promote its business in China. At the opening, the person in charge introduced that at present, China's pharmaceutical companies have invested only 1/6 of their investment in filtration, and they hope that this can be improved with the help of the GMP recertification opportunity. At the same time, he stated that more and more Chinese companies are currently undergoing international certification, and multinational suppliers can not only provide equipment products, but also provide corresponding consulting services and construction proposals, which are all powerful strengths to compete with domestic counterparts.
Provide international standard products and services and provide localized joint development services. In the new round of industrial upgrading, the win-win situation of the pharmaceutical industry and its multinational suppliers has begun to take shape.